June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Fluorescein and OCT Angiographic Evaluation of Choroidal Neovascular Membrane Following Proton Beam and Intravitreal Anti-VEGF Therapy for Exudative AMD: 2-year Follow Up
Author Affiliations & Notes
  • Sophia Wong
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • Inder Daftari
    Radiation Oncology, University of California, San Francisco, San Francisco, California, United States
  • Kavita Mishra
    Radiation Oncology, University of California, San Francisco, San Francisco, California, United States
  • Justin V Migacz
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • Iwona Gorczynska
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • Ala Moshiri
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • John S Werner
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • Susanna S Park
    Ophthalmology, University of California, Davis, Sacramento, California, United States
  • Footnotes
    Commercial Relationships   Sophia Wong, None; Inder Daftari, None; Kavita Mishra, None; Justin Migacz, None; Iwona Gorczynska, None; Ala Moshiri, None; John Werner, None; Susanna Park, None
  • Footnotes
    Support  NEI R01 024239; Strategic Opportunities Support Award (UCSF Clinical and Translational Science Institute)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 370. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sophia Wong, Inder Daftari, Kavita Mishra, Justin V Migacz, Iwona Gorczynska, Ala Moshiri, John S Werner, Susanna S Park; Fluorescein and OCT Angiographic Evaluation of Choroidal Neovascular Membrane Following Proton Beam and Intravitreal Anti-VEGF Therapy for Exudative AMD: 2-year Follow Up. Invest. Ophthalmol. Vis. Sci. 2017;58(8):370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess changes in choroidal neovascular membrane (CNVM) on fluorescein angiography (FA) and OCT angiography (OCTA) in eyes with exudative AMD (eAMD) following treatment with low dose proton beam irradiation (PBT) combined with intravitreal anti-VEGF therapy

Methods : Of 30 subjects with eAMD enrolled in a 2-year prospective, sham-controlled, randomized study of PBT combined with intravitreal anti-VEGF (ranibizumab 0.5mg or bevacizumab 1.25mg), interim subset analysis of subjects completing 2-year examination, FA and OCTA were reviewed. All eyes showed new subfoveal CNVM at enrollment, and were randomized 1:1:1 to sham radiation, 16 GyE PBT, or 24 GyE PBT. Patients received 3 monthly anti-VEGF treatments and were followed monthly for 24 months. Retreatment with anti-VEGF was given as needed for macular hemorrhage or fluid on OCT. FAs at baseline and month 24 were compared for change in CNVM size or leakage. Research-grade OCTA was performed to evaluate retinal, choroidal and CNVM vascular flow at follow up. The number of intravitreal anti-VEGF injections was recorded.

Results : Ten subjects had FA at month 24 (5 received sham radiation, 4 received 24 GyE, 1 received 16 GyE). The mean (+/- SEM) baseline CNVM size was 5.64 +/- 1.56 mm2 (0.19 to 14.87). The mean change in CNVM size was 45% +/- 29% (-24% to 134%) in the sham group, and 30% +/- 53% (-74% to 173%) in the 24 GyE group (p=0.81). The mean area of maximum leakage on FA at baseline was 5.94 +/- 1.76 mm2 (0.68 to 17.66). The mean change in CNVM leakage area on FA compared to baseline was 29% decrease in the sham group and 91% decrease in the 24 GyE group (p=0.34). The number of anti-VEGF administrations among the PBT treated eyes was 4.8 +/- 1.3 (3 to 7), versus 8.6 +/- 1.8 (6 to 14) in the sham group (p=0.14). OCTA was performed in 4 eyes; all showed normal retinal vascular flow on OCTA with reduced detectable flow within CNVM after PBT.

Conclusions : Although this interim subset analysis of an ongoing Phase I/II study showed no significant difference in change of CNVM size among eAMD eyes treated with anti-VEGF monotherapy when compared to eyes treated with combination PBT and anti-VEGF, there was a trend for greater reduction in CNVM leakage and less need for anti-VEGF in eyes treated with combination therapy, which partly may be from reduced CNVM vascular flow.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×